| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Collaboration revenue | NaN | 0 | 0 | 0 |
| Research and development | 7,575,000 | 4,104,000 | 5,011,000 | -430,000 |
| General and administrative | 4,412,000 | 6,996,000 | 3,218,000 | 3,122,000 |
| Total operating expenses | 11,987,000 | 11,100,000 | 8,229,000 | 2,692,000 |
| Loss from operations | -11,987,000 | -11,100,000 | -8,229,000 | -2,692,000 |
| Interest expense | 674,000 | 6,000 | 19,000 | 29,000 |
| Change in fair value of warrant liability | NaN | 3,500,000 | NaN | NaN |
| Interest and other income, net | 486,000 | -40,000 | 36,000 | 654,000 |
| Change in fair value of warrant and conversion option liabilities | -91,000 | NaN | NaN | NaN |
| Net loss and comprehensive loss | -12,266,000 | -14,646,000 | -8,212,000 | -2,067,000 |
| Basic EPS | -8.94 | -19.105 | -14.58 | -3.5 |
| Diluted EPS | -8.94 | -19.105 | -14.58 | -3.5 |
| Basic Average Shares | 1,372,084 | 766,598* | 563,066 | 591,137 |
| Diluted Average Shares | 1,372,084 | 766,598* | 563,066 | 591,137 |
SPRUCE BIOSCIENCES, INC. (SPRB)
SPRUCE BIOSCIENCES, INC. (SPRB)